During a Targeted Oncology™ Case-Based Roundtable™ event, Jonathan Abbas, MD, discussed data on therapies for a patient with polycythemia vera who did not adequately respond to hydroxyurea.
Abbas Weighs Options in Patient With JAK2-Mutate... - MPN Voice
Abbas Weighs Options in Patient With JAK2-Mutated Polycythemia Vera
Written by
Manouche
To view profiles and participate in discussions please or .
Read more about...
5 Replies
•
A good endorsement for Rux in PV. They note that the lower dose (2x 10mg) is less than the 20 used for MF, hence fewer negative events.
10 years ago there were MPN specialists who considered it unethical not to offer ET and PV patients interferon as a first line treatment:
ethical
He was right. This simple measure could have saved/prolonged the life of many PV sufferers.
Not what you're looking for?
You may also like...
Anyone with both GCA and also Polycythemia Vera ?
Is there anyone on this group who has GCA alongwith the MPN Polycythemia Vera ?
Bomedemstat in Patients With Polycythemia Vera
This is a Phase 2 open label study of an orally administered LSD1 inhibitor, bomedemstat...
Ropeginterferon Alfa-2b listed as Preferred Treatment in Polycythemia Vera
The National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology have been...
Ruxolitinib Provides Better Efficacy Than Best Available Therapy in Polycythemia Vera
« Patients with polycythemia vera (PV) achieved greater hematocrit control and improvement in...
Just been diagnosed with Polycythemia Vera
Only just signed up following confirmation last week that I have Polycythemia Vera and the JAK 2...
Related Posts
diagnosed with Polycythemia Vera - Clinical impact of mutated JAK2 allele burden reduction in polycythemia vera and essential thrombocythemia
- Next Steps for Research With Interferon-Alpha in Polycythemia Vera
- ASH 2019 | Ropeg in polycythemia vera: long-term PROUD-PV and CONTI-PV results
- JAK2V617F allele burden in polycythemia vera: burden of proof
